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Efficient and safe induction of CD8+ T cell responses is a desired characteristic of vac-
cines against intracellular pathogens. To achieve this, a new generation of safe vaccines 
is being developed accommodating single, dominant antigens of pathogens of interest. 
In particular, the selection of such antigens is challenging, since due to HLA polymor-
phism the ligand specificities and immunodominance hierarchies of pathogen-specific 
CD8+ T cell responses differ throughout the human population. A recently discovered 
mechanism of proteasome-mediated CD8+ T cell epitope generation, i.e., by protea-
some-catalyzed peptide splicing (PCPS), expands the pool of peptides and antigens, 
presented by MHC class I HLA molecules. On the cell surface, one-third of the presented 
self-peptides are generated by PCPS, which coincides with one-fourth in terms of abun-
dance. Spliced epitopes are targeted by CD8+ T cell responses during infection and, like 
non-spliced epitopes, can be identified within antigen sequences using a novel in silico 
strategy. The existence of spliced epitopes, by enlarging the pool of peptides available 
for presentation by different HLA variants, opens new opportunities for immunotherapies 
and vaccine design.
Keywords: antigen processing, CD8+ T  cell, epitope, intracellular pathogens, proteasome, peptide splicing, 
vaccine
inTRODUCTiOn
Infection with most viruses and bacteria elicits a protective immune response that eradicates the 
pathogen and provides immunity to subsequent infections. Vaccination approaches aim to trigger 
similarly protective immune responses, but usually fail to activate the broad range of immune effector 
mechanisms reacting to natural infection. For example, most vaccines are designed and/or tested for 
Abbreviations: cTECs, cortical thymic epithelial cells; EBV, Epstein–Barr virus; ERAP, endoplasmic reticulum aminopeptidase; 
MHC-I, MHC class I; PCPS, proteasome-catalyzed peptide splicing; PlcB, phosphatidylcholine-preferring phospholipase-C 
(PC-PLC); TAP, transporter associated with antigen processing.
FiGURe 1 | Proteasome-catalyzed peptide splicing (PCPS). PCPS may occur in different ways. (A) The two splice reactants can be generated by proteasome-
mediated cleavage of a single peptide sequence (cis-PCPS), the excision of the sequence between the two splice reactants (namely the intervening sequence), 
followed by the ligation of the splice reactants in normal order, i.e., following the orientation from N- to C-terminus of the parental protein (normal cis-PCPS), or in the 
reverse order (reverse cis-PCPS). We here graphically report the formation of the spliced epitopes gp100mel40-42/47-52 (2) and gp100mel47-52/4042 (5). (B) PCPS can occur 
between two splice reactants originating from two distinct proteins (trans-PCPS) (6, 7). Although the latter occurs in vitro (6–8), its occurrence in cells is disputable (7). 
We here show the example of the spliced peptide gp100mel35-39/35-39, which has been identified in in vitro digestions of synthetic substrate by purified proteasomes (9).
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capacity to elicit humoral responses, but intracellular pathogens, 
once they have entered their target cells in infected hosts, are 
eliminated by T cells only. Currently, the design of safe vaccines 
that induce protective T  cell immunity, capable of monitoring 
new infections, remains challenging. One of the reasons is that 
T cells of different individuals target different pathogen-derived 
epitopes. Although advanced prediction programs exist for the 
identification of such epitopes, a larger percentage of proteins 
seem not to contain any epitope candidates that may trigger a 
protective T cell response. In this mini review, we will focus on 
a recently discovered mechanism underlying T  cell-mediated 
immune recognition. Proteasomes, the proteases that generate 
most peptide epitopes presented to CD8+ T  cells (1), not only 
degrade proteins but also paste non-contiguous sequences of 
a given antigen back together (2, 3). This mechanism is called 
proteasome-catalyzed peptide splicing (PCPS) (Figure 1). PCPS 
is a frequently occurring process and, importantly, expands the 
potential epitope pool significantly [for review, see Ref. (4)]. 
We here discuss the opportunities and implications of PCPS for 
pathogen-specific immune protection and vaccine design.
SiGnALinG invADeRS
CD8+ T  cells play an important role in immune protection to 
intracellular pathogens, including viruses and intracellular bac-
teria, and tumor growth. To signal infection or other intracellular 
aberrations, cells exploit the ubiquitin proteasome system, which 
safeguards the cellular proteome by degrading the majority of 
unfolded, immature, obsolete, and short-lived mature proteins 
located in the cytoplasm (1). Peptide fragments released from 
the proteasome may bind the transporter associated with antigen 
processing (TAP) for translocation into the ER. Here, they may 
undergo N-terminal trimming by endoplasmic reticulum amin-
opeptidases and be loaded into the antigen-presenting groove of 
MHC class I (MHC-I) molecules, if they contain an appropriate 
MHC-I-binding motif. Peptide loading stabilizes MHC-I mol-
ecules, which then traffic to the cell surface for display of the 
peptides to CD8+ T cells.
The proteasome, by processing most MHC-I-presented ant-
igens, shapes the antigenic peptide repertoire available for binding 
to MHC-I complexes. This is illustrated by the fact that—although 
the antigenic peptides monitored by CD8+ T  cells at the cell 
surface are influenced by the specificity of each step of the anti-
gen presentation pathway—the two major factors selecting the 
MHC-I immunopeptidome are the affinity of the peptides for the 
cleft of the different MHC-I variants and proteasome cleavage 
specificity (10–13).
The proteasome can hydrolyze almost any peptide bond, but 
with a large range of efficiencies, resulting in huge differences 
in quantity between specific peptide products. One of the main 
cellular mechanisms to alter the peptide repertoire, produced by 
proteasomes, is by changing the cell’s proteasome isoform con-
tent (14). The proteasome is a multi-catalytic enzyme complex, 
composed of a 20S core particle, responsible for proteolysis, and 
different regulatory complexes, including the 19S regulatory 
complex, which is responsible for substrate capture and unfolding 
in an ATP-dependent manner [for review, see Ref. (1, 14)]. The 
20S catalytic core consists of four stacked rings of seven subunits 
each, with catalytic activity exerted by three β subunits—i.e., β1, 
β2, and β5—present in the inner two rings of this particle. Under 
stress conditions and cytokine exposure, these subunits can be 
replaced by their inducible homologs LMP2/iβ1, MECL-1/iβ2, 
and LMP7/iβ5, leading to the formation of immunoproteasomes. 
Depending on cell type and levels of constitutive or induced 
LMP2/iβ1, MECL-1/iβ2, and LMP7/iβ5 subunit expression, cells 
often possess “mixed proteasomes,” which contain both standard 
and inducible catalytic β subunits (14). In addition, cortical thymic 
epithelial cells incorporate the thymus-specific β5t subunit in 
their proteasomes, probably to support the unique role of these 
cells in positive selection of CD8+ T cells (14–16). The exchange of 
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the catalytic β subunits largely affects the proteolytic dynamics of 
the proteasome (17) and thus, depending on cytokine milieu and 
expressed proteasome isoforms, different peptide products will 
predominate among the repertoire of peptides produced. These 
quantitative differences in the generation of specific peptides, by 
the different proteasome isoforms, can mark the immunogenicity 
of the individual peptides, i.e., quantitative differences in epitope 
generation can determine whether a specific T  cell response is 
primed, and greatly affect the immunodominance hierarchy of 
CD8+ T cells responding to infection, as demonstrated in mouse 
models (18–22).
PCPS AnD iTS POTenTiAL ReLevAnCe 
in CD8+ T CeLL ReSPOnSe DURinG 
inFeCTiOn
The active site of the catalytic proteasome β subunits is formed by 
a threonine (T) residue at position 1 of the mature form of these 
enzymes. This T1 catalyses the break of the peptide bond between 
two residues of a substrate, thereby leading to the formation of 
an acyl-enzyme intermediate between the active site T1 and the 
N-terminal portion of the substrate. The C-terminal peptide frag-
ment is then released. For a long period, it was assumed that the 
N-terminal portion of the substrate would always be released by 
hydrolysis. However, more than a decade ago, it was discovered 
that not only an H2O molecule but also the NH2-terminus of an 
earlier produced peptide—i.e., the C-terminal splice reactant 
(Figure 1)—can compete with a H2O molecule to attack the acyl-
enzyme intermediate. This then results in a peptide bond between 
the N-terminal portion of the substrate—i.e., the N-terminal 
splice reactant—and the C-terminal splice reactant. A new, 
spliced peptide is thereby formed and released by the proteasome 
(2, 6) (Figure  1). This transpeptidation reaction is likely to be 
the most frequent reaction type of PCPS and was demonstrated 
to contribute to the generation of a handful of tumor epitopes 
(4). Because of the small number of spliced epitopes described in 
over a decade, it was believed that PCPS was a rare event of no 
immunological relevance. However, recent findings demonstrat-
ing that around 30% of the MHC-I immunopeptidome variety of 
Epstein–Barr virus (EBV)-immortalized B cell lines and primary 
human fibroblasts is represented by spliced peptides (23) sug-
gested the contrary. Although it still has to be proven that this 
phenomenon occurs in such great extent also in other cell types, 
spliced peptides are likely to fulfill an immune-relevant function 
during the immune response against infections.
First evidence supporting this hypothesis was obtained in 
a murine model of infection by the intracellular bacterium 
Listeria monocytogenes. We showed that CD8+ T  cells, specific 
for an immunodominant epitope derived from the listeriolysin 
O antigen, cross-recognized an overlapping peptide produced by 
proteasome-mediated splicing of the LLO sequence (Figure 2A) 
(24). These data illustrated that CD8+ T cells responding to infec-
tion could recognize both non-spliced and spliced variants of 
the same epitope, but did not strictly prove that PCPS increased 
the immune-relevant epitope pool. The latter was addressed in 
a second study, identifying two spliced epitopes derived from 
the Listeria phosphatidylcholine-preferring phospholipase-C 
(Plc)B protein (25). These spliced epitopes, i.e., PlcB189-191/163-167 
and PlcB189-192/164-167 (Figure 2B), triggered a specific CD8+ T cell 
response in L. monocytogenes-infected mice that could not be 
explained by any cross-reactivity toward non-spliced peptides 
of the same antigen or other antigens of the L. monocytogenes. 
Furthermore, mutation of the MHC-I anchor sites of these two 
spliced epitopes, within the PlcB antigen, abolished recogni-
tion of PlcB-transfectant cells by CD8+ T cells of infected mice, 
suggesting that the two spliced epitopes dominate the response 
against the PlcB antigen during L. monocytogenes infection (25).
These sparse data prompt the question whether spliced 
epitopes are just an extra pool of antigenic peptides, largely 
overlapping with the non-spliced peptide pool, or whether they 
exert a broader immune-relevant function. The fact that two 
spliced epitopes drive the response of the CD8+ T cells toward 
the PlcB antigen during L. monocytogenes infection (25) would 
suggest a broader function. For instance, it should be noted that 
various spliced epitope candidates that may be produced from 
Listeria PlcB largely exceeds that of non-spliced peptides, as 
calculated for both the mouse MHC-I H-2Kb molecule and the 
most frequent human MHC-I HLA-A and -B variants. In these 
in silico analyses, no non-spliced epitope candidates predicted to 
efficiently bind the predominant MHC-I variants were identified 
within the PlcB sequence, in opposite to hundreds of potential 
spliced epitope candidates (25). The potential immune relevance 
of spliced epitopes in enlarging the antigenic landscape of cells 
is further supported by the finding that one-third of human 
self-antigens is represented only as spliced peptides within the 
MHC-I immunopeptidomes of EBV-immortalized B  cell lines 
and primary human fibroblasts (23). Moreover, with one-third 
of spliced peptides occupying one-fourth of the available MHC-I 
molecules, compared to two-thirds of non-spliced peptides occu-
pying three-fourth of MHC-I molecules of the cell types investi-
gated so far (23), the differences in quantity between spliced and 
non-spliced antigenic peptides may be rather small. In line with 
this assumption, Ebstein et al. (5) quantified the presence, at the 
cell surface, of gp100mel-derived spliced and non-spliced epitopes 
endogenously generated by proteasomes, using specific CD8+ 
T  cell clones. Despite substantial differences between epitopes, 
spliced and non-spliced epitopes were presented in comparable 
amounts.
Thus, spliced epitopes should be equally likely to trigger CD8+ 
T  cell responses as non-spliced epitopes. In addition, spliced 
epitopes that could be considered as variants of non-spliced 
epitopes, like LLO294/297-304, may either serve as alternative ligand 
for CD8+ T cells primed by the non-spliced epitope or, perhaps, 
serve as antagonists, dampening the antigen-specific CD8+ T cell 
response.
TOOLS FOR THe PReDiCTiOn  
OF SPLiCeD ePiTOPeS
Further studies into the immunological relevance of spliced 
peptides would benefit from in silico tools for predicting spliced 
epitope candidates within protein sequences of interest. However, 
FiGURe 2 | Generation of Listeria-derived spliced epitopes LLO291-294/297-304, PlcB189-192/164-167, and PlcB189-191/163-167. (A) Structure of LLO of Listeria monocytogenes with 
LLO291-294/297-304 highlighted. Proteasome-catalyzed peptide splicing (PCPS) generates the spliced epitope precursor LLO291-294/297-304. This peptide is N-terminally 
truncated by ERAP1 which results in LLO294/297-304 (24). (B) L. monocytogenes PlcB189-192/164-167 and PlcB189-191/163-167 are generated from the secreted bacterial virulence 
factor PlcB via reverse cis-PCPS (25).
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the combinatorial possibilities of spliced peptide generation 
are so many that without a preliminary in  silico strategy, any 
analysis would be challenging. We recently developed and tested 
an in silico approach for spliced epitope identification, using the 
murine model of Listeria infection (25). As target antigens, we 
selected two small, secreted virulence factors, PlcA and PlcB, 
and calculated all possible spliced peptides originating from 
these proteins. Some restrictions were introduced, based on 
previous studies, i.e., we selected only spliced peptides that are 
8 or 9 residues long, representing the typical length of peptides 
presented by mouse MHC class I molecules. Furthermore, we 
allowed: (i) 40 residues as maximal intervening sequence length; 
(ii) only cis-PCPS, which seems to be more common than trans-
PCPS in living cells; and (iii) that the splice reactants can be 
spliced in either the same or reverse order as occurring in the 
antigen of interest (Figure 1). The resulting reduced spliced pep-
tide database was then analyzed using the online available SMM 
prediction tool for MHC-I-peptide binding affinity, to select 
peptides with high binding affinity for mouse H-2Kb molecules. 
Setting a cutoff for binding affinity at 16 nM, 22 spliced epitope 
candidates were selected and tested ex vivo for recognition by 
splenic CD8+ T cells of L. monocytogenes-infected mice. These 
experiments identified two spliced peptides, PlcB189-191/163-167 
and PlcB189-192/164-167, as targets of the Listeria-specific CD8+ 
T  cell response. Selecting the final spliced epitope candidates 
in  silico, based on their low predicted IC50, showed to be the 
right approach since PlcB189-191/163-167 and PlcB189-192/164-167 were 
the two peptides, ranked as the highest affinity binders (25). 
Thus, we observed a correlation between predicted IC50 (and 
H-2Kb—peptide complex stability) and priming of specific CD8+ 
T cells during infection, consistent with earlier published works 
on non-spliced epitopes (11–13).
Despite the positive results of the above study, the applied 
MHC-I-peptide-binding affinity predictions could represent a 
problem, because the most efficient MHC-I-peptide-binding 
affinity prediction algorithms have been trained on non-spliced 
epitope databases. PCPS and cleavage preferences significantly 
differ in term of substrate sequence motifs (6). Thus, it is possible 
that the canonical sequence motif of the non-spliced antigenic 
peptides bound to a given MHC-I variant differ from that of 
the spliced antigenic peptides. This seemed to be the case for 
the MHC-I immunopeptidomes of the EBV-immortalized B cell 
lines and primary human fibroblasts (23). Probably, a great 
improvement will come from studying the sequence motifs pre-
ferred by PCPS. A first attempt in that direction has been done 
by Berkers et al. (8). Using small peptide libraries, composed of 
C- and N-terminal splice reactants carrying one of two required 
HLA-A*02:01 anchor residues, and HLA-A*02:01 molecules 
coupled with a chemosensitive ligand as read out, the authors 
defined which residues at P2′ and P1′, and P1 and P2 position 
most efficiently promote PCPS. Thereby, they confirmed that 
rather than being a random process, PCPS is finely regulated 
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by the substrate sequence. This specificity could be explained 
by the binding of the splice reactants to PCPS-binding sites of 
the proteasome nearby its catalytic T1 (6). However, Berkers’ 
approach was restricted to an epitope backbone sequence that 
was used as a reference and variations of that sequence were 
tested in terms of PCPS efficiency. It is known that not only 
residues in proximity but also 10 residues away may affect the 
cleavage-site usage by proteasomes (21, 26). Hence, the use 
of a fixed backbone sequence could bias the outcome of the 
analysis and partially restrict the results to that model sequence. 
Furthermore, the outcome of that pioneering work is specific for 
the binding motifs of HLA-A*02:01 and could thus significantly 
differ for other HLA-I haplotypes.
We can reckon that the development of a PCPS prediction 
algorithm would benefit from a sequence unbiased approach, like 
provided by mass-spectrometry-based identification of spliced 
peptides in in  vitro digestions of synthetic polypeptides (or 
proteins) carried out with purified proteasomes. This approach 
was the basis for the definition of preferred sequence motifs of 
proteasome-mediated peptide hydrolysis (20, 27, 28). Such a 
quantitative approach, in future, may define the proteasome 
preferences in terms of cleavage and PCPS, and thereby facilitate 
further research on the immunological relevance of PCPS.
PCPS AnD CROSS-ReACTiviTY
Although spliced epitope-specific T cells most likely are selected 
in the thymus in a similar fashion as non-spliced epitope-specific 
T cells, PCPS offers so far unrecognized possibilities for cross-
reactivity of pathogen-specific CD8+ T  cell responses with 
self-antigens. Due to the limited research into PCPS-generated 
pathogen-derived epitopes, such auto-reactivity has not yet been 
shown for spliced epitope-specific CD8+ T  cells. However, in 
human T1D and mouse models of insulin-dependent diabetes 
mellitus, the autoreactive CD4+ T cell response has been shown 
to target trans-spliced self-epitopes [(29–31), and reviewed in 
Ref. (4)]. In addition, most spliced CD8+ T cell epitopes described 
up to date are derived from tumor-associated (self-)antigens, as 
discussed earlier. Thus, like for non-spliced epitopes, a spliced 
epitope-specific autoreactive T  cell repertoire certainly exists. 
Given the tremendous number of possibilities for epitope 
splicing, there is a conceivable chance for a minor fraction of 
pathogen-induced spliced epitope-specific CD8+ T cells to dis-
play auto-reactivity.
ReLevAnCe OF PCPS FOR vACCine 
DeSiGn
Proteasome-catalyzed peptide splicing is not a random process 
of ligating peptide sequences. On the contrary, preliminary 
evidence suggests that PCPS prefers specific peptide sequence 
motifs and that those motifs are not those preferred for the 
canonical peptide hydrolysis reaction (6, 8). This implies that the 
spliced and non-spliced epitope pools can differ in term of char-
acteristics and predisposition to bind specific HLA-I haplotypes. 
This can explain why a large portion of self-antigens seems to be 
represented at the cell surface only by spliced peptides (23). The 
few examples of MHC-I-spliced immunopeptidomes available 
so far do not allow us even to speculate if those antigens repre-
sented only by spliced peptides have either a peculiar intracel-
lular localization, specific chemical characteristics, or turnover. 
Moreover, we do not know whether this large representation of 
spliced peptide in the MHC-I self immunopeptidome occurs 
also in the MHC-I viral immunopeptidome. However, our pre-
liminary evidence that the mouse CD8+ T cell response against a 
specific L. monocytogenes antigen (PlcB) is driven only through 
spliced epitopes suggests that PCPS may open novel opportuni-
ties for vaccine design.
To improve the efficacy of vaccination, especially against 
“difficult to treat” and rapidly mutating intracellular pathogens, 
vaccines need to be redesigned to elicit pathogen-specific, 
protective CD8+ T cell responses. Currently, a new generation 
of live, safe, recombinant vaccine vectors that encode one or 
multiple small antigens, derived from the pathogen of interest, 
is evaluated for protective capacity (32–35). Nevertheless, the 
extensive polymorphism of the human HLA, resulting in differ-
ing epitope-specificities and immunodominance hierarchies of 
responding CD8+ T cells in different individuals, makes it dif-
ficult to predict which antigens will provide optimal protection 
within a larger percentage of the population. In silico analysis 
tools are frequently used to screen antigens, but may fail to 
predict relevant T cell epitopes that may induce a response in 
context of the majority of HLA-I haplotypes, as we illustrated for 
L. monocytogenes-derived PlcB (25). Including spliced peptides 
as potential epitopes could aid in this, by enlarging the number 
of potentially immune-relevant epitopes as well as the variety 
of pathogen’ antigens that can be used to trigger a robust and 
persistent immune response. Therefore, we can speculate that 
further research into the immunological relevance of spliced 
epitopes during the immune response against infections, as 
well as optimization of in silico tools to accurately predict such 
epitopes within antigen sequences, can bring remarkable ben-
efits for vaccine development.
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